Two layers of selectivity

OUR FUSOGENIC LNPs SELECT THE TARGET ORGAN –
OUR seRNA CONSTRUCTS SELECT THE TARGET CELL

seRNAs contain an antisense domain that matches to an RNA marker expressed in diseased cells.

In a cell that does not carry the marker, nothing happens. The construct stays silent and is cleared within hours.

In a cell that does, the sensor binds its target. The cell degrades the resulting double strand, the block on the expression element falls away, and the effector is produced – in that cell only.

Because sensor and effector are separate modules, the same architecture can eliminate a cancer cell, reprogram a fibrotic one, or deplete a defined immune cell class.

Inside the seRNA construct

seRNAs have a modular design. Each module is performing its conserved function.

Conventional mRNA starts translation at its cap. seRNA does not.
The effector sits behind an internal ribosome entry site, and that site is held shut by a blocker element.
Only the sensor binding its target RNA removes the blocker and releases translation.

This gating is what makes the construct silent by default – and it is the part most comparable approaches do not have.

Fusogenic delivery to the target organ

Most lipid nanoparticles are taken up into endosomes, where much of their cargo is degraded before it can act. Our fusogenic LNPs merge with the cell membrane instead and release seRNA directly into the cytosol. Formulation is straightforward, and particle composition sets which organ the dose reaches – hepatic and extrahepatic.

Organ-specific targeting

Efficient cellular uptake

Direct cytosolic release

Straightforward formulation

  • Organ-specific targeting

  • Efficient cellular uptake

  • Direct cytosolic release

  • Straightforward formulation

Active only where the disease-specific marker is

In cells without the RNA marker, seRNA stays inactive and is cleared.

In cells with it, the effector is expressed locally.

Because healthy tissue is spared, effectors can be used that would be too toxic if expressed everywhere.

  1. In cells without the RNA marker, seRNA stays inactive and is cleared.
  2. In cells with it, the effector is expressed locally.
  3. Because healthy tissue is spared, effectors can be used that would be too toxic if expressed everywhere.

Our Publications

First page of the Nature Communications article
Nature Communications · 2025

Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting

Rastfeld F., Hoffmann M., Krüger S., et al.
Nat Commun 16, 420 (2025)

Read paper
First page of the Pharmaceutics article
Pharmaceutics · 2025

Robust functionality and regulation of selectively expressed RNA as AAV vectors and in vitro transcribed molecules

Rastfeld F., Hersch N., Dreissen G., et al.
Pharmaceutics 17(12), 1595 (2025)

Read paper